Therapeutic Class
Nucleoside Reverse Transcriptase Inhibitor (NRTI)

Indication
Treatment of HIV-1 infection in adults and adolescents as part of combination antiretroviral therapy (ART), in accordance with WHO and NACO recommendations.

Dosage & Administration
300 mg twice daily or 600 mg once daily, or as prescribed by a healthcare professional.

To be used strictly as part of a combination ART regimen.

Storage
Store below 30°C in a dry place, protected from light and moisture.

Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.